Page 1

AC Immune PRESS RELEASE AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update Announced strategic acquisition of industry - leading Parkinson's disease vaccine and equity investment led by key investors in Covid - 19 vaccine innovator BioNTech SE ACI - 24 full Phase 1b results presented at AAIC 2021 support the continued clinical development of anti - Abeta vaccine approaches in Down syndrome - related Alzheimer's disease Expanded Phase 1b / 2 anti - pTau Alzheimer's vaccine trial in collaboration with Janssen Pharmaceuticals , Inc. to support the program's continued development Strong financial position of CHF 199.1 million in cash ensures the Company is fully financed through at least Q1 2024 _ Lausanne , Switzerland , August 4 , 2021 AC Immune SA ( NASDAQ : ACIU ) , a clinical - stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases , today reported its financial results for the quarter ended June 30 , 2021 , and provided a corporate update . Prof. Andrea Pfeifer , CEO of AC Immune SA , commented : " AC Immune continues its expansion with the transformative acquisition of PD01 , which significantly strengthens our active vaccines portfolio by adding a clinically validated candidate in Parkinson's disease , whilst maintaining a strong financial position of CHF 199.1 million in cash . In Q1 , the Company released positive data on the safety and immunogenicity of ACI - 24 and ACI - 35.030 , our anti - Abeta and anti - Tau vaccines in Alzheimer's disease . We firmly believe that a vaccine approach coupled with the right diagnostic tools can bring an alternative therapeutic approach to prevent neurodegenerative diseases in large populations , like for Covid - 19 . " Q2 2021 and Subsequent Highlights Announced an all - stock acquisition of Affiris ' portfolio of therapeutics targeting alpha- synuclein notably PD01 , a clinically validated active vaccine candidate that places AC Immune at the forefront of Parkinson's disease drug development . Through the planned acquisition and a concurrent financing , AC Immune will also strengthen its cash position and add Athos Service GmbH ( Strüngmann family office ) , First Capital Partner GmbH ( Egger Family Office ) , and MIG Fonds , the three lead investors in Covid - 19 vaccine innovator BioNTech SE , to its shareholder base . Presented the full results from the landmark Phase 1b clinical trial evaluating the anti - Abeta vaccine ACI - 24 in subjects with Down syndrome at the Alzheimer's Association International Conference ( AAIC ) 2021 , showing that ACI - 24 generated evidence of immunogenicity along with a positive pharmacodynamic response and a favorable safety and tolerability profile . Based on these results , the Company plans to advance an optimized 1/8